论文部分内容阅读
[目的]评价微生态制剂治疗肝性脑病的疗效和安全性。[方法]采用计算机检索方式,检索Medline、PubMed、Embase、中国生物医学文献数据库、维普中文科技期刊全文数据库和中国期刊全文数据库,纳入微生态制剂治疗肝性脑病的随机对照试验(RCT),采用Revman 5.2软件对资料进行系统分析。[结果]共纳入7篇RCT,包括604例患者。分析显示:微生态制剂能有效提高患者的临床缓解率,明显降低血氨水平,改善数字连接试验(NCT-A),与乳果糖制剂相比两者效果相似,而明显优于安慰剂/空白对照组,且总体不良反应少。[结论]现有的临床证据表明,微生态制剂对于治疗肝性脑病疗效肯定,可以作为临床治疗的一种选择。
[Objective] To evaluate the efficacy and safety of probiotics in the treatment of hepatic encephalopathy. [Methods] The randomized controlled trials (RCTs) for the treatment of hepatic encephalopathy were included in the methods of computer retrieval, Medline, PubMed, Embase, Chinese Biomedical Literature Database, VIP Chinese Journal Full-text Database and Chinese Journal Full- Revman 5.2 software for systematic analysis of the data. [Results] A total of 7 RCTs were included, including 604 patients. Analysis showed that: probiotics can effectively improve the clinical remission rate, significantly lower blood ammonia levels, improve the digital connection test (NCT-A), compared with lactulose preparations, the two are similar, but significantly better than placebo / blank Control group, and the overall adverse reactions less. [Conclusion] The available clinical evidence shows that the probiotics have a positive effect on the treatment of hepatic encephalopathy and may be used as an option for clinical treatment.